Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women
NCT ID: NCT00406640
Last Updated: 2023-12-28
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
595 participants
INTERVENTIONAL
2006-12-31
2008-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Desvenlafaxine succinate sustained-release (DVS SR)
flexible dose of DVS 50-100 or 200 mg every day during 56 days. Extension until 6 months.
B
Escitalopram
Flexible dose of Escitalopram 10 or 20 mg every day during 56 days. Extension until 6 months.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Desvenlafaxine succinate sustained-release (DVS SR)
flexible dose of DVS 50-100 or 200 mg every day during 56 days. Extension until 6 months.
Escitalopram
Flexible dose of Escitalopram 10 or 20 mg every day during 56 days. Extension until 6 months.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A primary diagnosis of MDD, single or recurrent episode, without psychotic features using the modified MINI International Neuropsychiatric Interview (MINI).
* Montgomery-Asberg Depression Rating Scale (MADRS) total score \> or = 22 at the screening and baseline visit.
Exclusion Criteria
* Current (within 12 months) psychoactive substance abuse or dependence (including alcohol), manic episode, post-traumatic stress disorder, obsessive-compulsive disorder, or a lifetime diagnosis of bipolar or psychotic disorder.
* A history or active presence of clinically important medical disease.
Additional criteria apply.
40 Years
70 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wyeth
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Wyeth is now a wholly owned subsidiary of Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Richmond, Virginia, United States
Morgantown, West Virginia, United States
Middleton, Wisconsin, United States
Buenos Aires, , Argentina
Buenos Aires, , Argentina
Buenos Aires, , Argentina
Buenos Aires, , Argentina
Buenos Aires, , Argentina
Buenos Aires, , Argentina
Buenos Aires, , Argentina
La Plata, , Argentina
Mendoza, , Argentina
Santiago, , Chile
Barranquilla, , Colombia
Bogotá, , Colombia
Bucamaranga, , Colombia
Mexico City, , Mexico
Monterrey, , Mexico
Tobasco, , Mexico
Chiclayo, , Peru
Lima, , Peru
Peoria, Arizona, United States
Pasadena, California, United States
San Diego, California, United States
San Diego, California, United States
Denver, Colorado, United States
Cromwell, Connecticut, United States
Farmington, Connecticut, United States
Waterbury, Connecticut, United States
Brooksville, Florida, United States
Coral Springs, Florida, United States
Fort Myers, Florida, United States
Gainesville, Florida, United States
Maitland, Florida, United States
Atlanta, Georgia, United States
Roswell, Georgia, United States
Northfield, Illinois, United States
Oak Brook, Illinois, United States
Overland Park, Kansas, United States
Wichita, Kansas, United States
New Orleans, Louisiana, United States
Shreveport, Louisiana, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
Fall River, Massachusetts, United States
Saint Paul, Minnesota, United States
Las Vegas, Nevada, United States
Piscataway, New Jersey, United States
Elmsford, New York, United States
Hollis, New York, United States
New York, New York, United States
New York, New York, United States
Syracuse, New York, United States
Raleigh, North Carolina, United States
Oklahoma City, Oklahoma, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
East Providence, Rhode Island, United States
Lincoln, Rhode Island, United States
Charleston, South Carolina, United States
Columbia, South Carolina, United States
Mt. Pleasant, South Carolina, United States
Memphis, Tennessee, United States
Bellaire, Texas, United States
Dallas, Texas, United States
Denton, Texas, United States
Houston, Texas, United States
Burlington, Vermont, United States
Charlottesville, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Soares CN, Thase ME, Clayton A, Guico-Pabia CJ, Focht K, Jiang Q, Kornstein SG, Ninan PT, Kane CP. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram. CNS Drugs. 2011 Mar;25(3):227-38. doi: 10.2165/11586460-000000000-00000.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3151A1-402
Identifier Type: -
Identifier Source: org_study_id